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The  C3  proactivator  (C3PA)  is  cleaved and converted to  an active enzyme 
capable  of  acting  on  C3  when  serum  is  treated  with  yeast  cell  walls,  inulin, 
endotoxin,  or  aggregates  of certain immunoglobulins  (1).  Activation  of  C3PA 
was  postulated  to  be  effected  by  a  serum  enzyme  called  C3PA  convertase 
(C3PAse).  We  now wish  to  report  (a)  the identification of  C3PAse  in human 
serum  as  a  3S ix-globulin and  (b)  the finding that  C3PAse  action  requires  the 
presence  of  a  product  of  C3.  The  possibility  is  raised  therefore  that  the  C3 
activator system is governed by a  positive feedback mechanism. 
Materials  and Methods 
Isolated Proteins.--C3  (2)  and C3PA  (1)  were isolated from human serum as described. 
C3 was utilized at a concentration of 2.6 mg/ml and C3PA at 400/~g/ml. 
Isolation  of Activated Hydrazine-Sensitive  Factor (HSFa).--The  euglobulins of  2.4  liters 
of outdated plasma were chromatographed on a  5.5  X  67  cm column of DE32 equilibrated 
with 0.005 ~  phosphate buffer, pH 7.3. This buffer and all other buffers used contained 0.002 
M ethylenediaminetetraacetate (EDTA). HSFa was eluted by NaC1 gradient in a conductance 
range of 7-11 mmho. The active material was then applied to a 2.5 X  95 cm column of Sepha- 
dex  G-200  (Pharmacia Fine Chemicals,  Inc.,  Piscataway,  N.  J.)  equilibrated with 0.15 
NaC1 containing 0.005 ~  phosphate buffer, pH 7.3.  HSFa was eluted with the second protein 
peak which was further chromatographed using a  2.2  X  34 cm column of BioRex 70  (Bio- 
Rad  Labs.,  Richmond,  Calif.)  equilibrated with 0.03  ~  phosphate  buffer,  pH  7.0. HSFa 
was eluted with starting buffer and emerged immediately after the firs t protein peak. 
HSFa was utilized at a  concentration of 0.08 mg/ml. 0.2 ml portions were subjected to 
alkaline disc  electrophoresis on 6%  gels.  The gels were  sliced longitudinally; one-half was 
stained for protein, the other cut into 2 mm segments which were eluted with 0.1 ml Veronal 
buffer for activity testing. Antiserum to HSFa was  made  by immunizing rabbits with the 
isolated protein. 
Purification of C3PAse.--2  X  10 ml fresh human serum was separated by electrophoresis 
on Pevikon blocks in barbital buffer, pH 8.6,  P/2  =  0.05,  for 24 hr at 4°C  and 3.5 v/cm. 
Active fractions were pooled and concentrated by ultrafiltration to 2 ml, and the material 
was  further separated  by molecular sieve chromatography on  a  2.5  X  40  cm  column  of 
Sephadex  G-150 equilibrated with 0.15 ~t NaC1  in 0.005  ~  phosphate buffer, pH  7.3.  The 
active fractions were concentrated and portions of 0.2 ml containing 0.085 mg of protein were 
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subjected to polyacrylamide gel electrophoresis. The gels were sliced longitudinally; one-half 
was stained for protein, the other half cut into 2 mm segments which were eluted with 0.1 
ml Veronal buffer, pH 7.3, overnight at 4°C. Eluates were analyzed for C3PAse activity and 
by Ouchterlony test with antisera  to  the following proteins:  Gc (gift of Dr.  A. G. Bearn, 
Cornell University Medical College, New York), ~x2HS glycoprotein, c~1 acid glycoprotein 
(gifts from Behringwerke AG, Marburg-Lahn,  West Germany), and Cls. 
Assay of Hydrazine-Sensitive Factor (HSF).--N2H4-treated human serum was  used as a 
reagent (0.015 M N'_,H4 at 37°C for 60 min). 0.1 ml of serum fraction was added to 0.1 ml of 
N2H4 serum and 0.02 ml 50 mg/ml inulin suspension in sterile saline. The mixture was in- 
cubated  at 37°C for 30 min and the conversion of C3PA to C3 activator was evaluated by 
immunoelectrophoresis (IEP)  (1). The degree of conversion was  estimated  visually or by 
determining  the distribution  of radioactivity  in the IEP slide when  C3PA-125I had been 
added to the serum reagent. Alternatively, HSF activity was determined by lysis of gluta- 
tione-treated erythrocytes in presence of N2H4 serum and inulin (3). 
Assay of HSFa.--IO/~1 of HSFa was added to (a) 50 #l of whole human serum and 1/M 
of Me  ++ (0.015 :~ CaC12 and 0.03 ~ MgCI2 in saline), or (b) to 10/zl of C3PA, 10/zl of C3PAse, 
and 3 #l of Me++; the reaction mixtures were held at 37°C for 30 rain and evaluated as de- 
scribed above  (HSF). 
Assay of C3PAse.  Test solution (10/zl) was added to 10 #I of C3PA, 10 #1 of HSFa, and 
3 #1 of Me  ++. Treatment and evaluation were as described above. 
Assay of C3 Conversion by C3 Activator.--lO/zl of C3PA, 10/zl of C3PAse, 10 #1 of HSFa, 
and 5 #1 of Me  ++ were incubated with 20 #1 of C3 for 30 min at 37°C. IEP was performed 
using monospecific  anti-C3. 
RESULTS 
Identification of ttSF.--Treatment  of serum with N,.,H4 prevented conversion 
of C3PA upon subsequent incubation with inulin. Fractions of untreated serum 
were therefore tested for their capacity to reconstitute N2H4-treated serum in 
the  inulin test.  The  distribution of HSF  on chromatography of  serum using 
diethylaminoethy] cellulose or  Sephadex  G-200 was  found  to  correlate  with 
that of C3. When five different preparations of isolated human C3 were tested 
for HSF activity, they were all found to be active.  Further, the  distribution 
of  isolated  C3  protein  upon  Pevikon  block  electrophoresis  correlated  well 
with  that  of  HSF  activity. It was  concluded that  HSF  in the  C3  activator 
system is identical with native C3, a  protein known to be N2H4 sensitive (4). 
Isolation  of HSFa.--Exploration  of  serum  fractions  for  HSF  activity led 
to the recognition of another factor, HSFa, which caused conversion of C3PA 
in  N~H4-treated  or  untreated  serum  in  absence  of  inulin. This  factor  was 
isolated as described in the Materials and Methods section. On polyacrylamide 
gel electrophoresis the  preparation consisted essentially of  one major protein 
band and the  biological activity was  eluted exactly from the  location of  the 
protein disc (Fig. 1). Tested by the double diffusion in gel method it gave one 
precipitin line with  an  anti-whole human serum  which  fused  with  the  line 
produced with  an  anti-C3 and with  that  of  an  anti-HSFa. On immunoelec- 
trophoresis HSFa was  located  more  anodal than native C3  (Fig.  1),  and in 
mixture with  native C3,  both  lines fused,  with  native C3  extending a  spur 
over the HSFa line (not shown). Anti-HSFa when tested with whole human 
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the  s  rate  of HSFa  was  estimated  to  be  8.5S  (Fig.  2).  Its  activity  was  not 
abolished by N2H4 treatment.  Thus the activity to effect conversion of C3PA 
in  whole human serum appears  to reside  in  a  fragment  of C3 which with  re- 
spect  to  s  rate  and  electrophoretic  behavior  resembles  C3b.  It  may  be  con- 
sidered the activated form of HSF. In contradistinction  to its effect in serum, 
isolated HSFa was unable to cause conversion of isolated C3PA (Fig. 3). 
FIG.  ].  Analysis of isolated  HSFa.  (Left):  disc  electrophoresis on 6%  polyacrylamide 
gel. Anode was at the right.  HSFa activity was eluted from segments of the unstained  half 
of gel. (Right):  immunoelectrophoresis  of isolated  C3  (above) and  HSFa  (below); pattern 
developed with anfi-HSFa.  Anode was at the right. 
C3  Proaclivator  Convertase.--Using  C3PA and HSFa it was now possible  to 
screen  serum  fractions  for  C3PAse  activity.  This  activity  was  found  in  the 
a-globulin region of serum separated by Pevikon block electrophoresis  (Fig. 4). 
On density gradient ultracentrifugation  of the a-globulin fraction or of whole 
human  serum,  C3PAse sedimented  as  a  3S  component  (Fig.  2).  Disc electro- 
phoresis  of  a  partially  purified  preparation  of  C3PAse  allowed  identification 
of the enzyme with a discrete protein band. Identification with one of the known 
a-globulins  using  various  antisera  (see  Materials  and  Methods  section)  has 
failed  so far.  C3PAse is  distinct  from  Cls,  a  4S  a-globulin,  by activity  and 
immunochemical properties. 
C3PAse, in partially purified form or eluted from polyacrylamide gels, failed 
to  convert  isolated  C3PA,  but  it  effected  complete  conversion  of  C3PA  in 
in the presence of HSFa and metal  ions  (Fig.  3).  0.01 M EDTA inhibited  the 
reaction,  as did heparin  (1000  units/ml),  and epsilon  amino caproic  acid  (0.5 
M)  accelerated  it.  Native  C3,  when  free  of  conversion  products,  could  not 
substitute  for HSFa.  Further,  C3PA conversion could not be initiated  in mix- 
tures  with  C3PAse,  native  C3,  and  Me  ++,  by  the  addition  of  inulin,  which 
leads  to C3PA conversion in whole serum.  Native C3-converting activity was 
generated  during  incubation  at  37°C  of  C3PA,  C3PAse,  HSFa,  and  Me  ++ 
(Fig.  3). 
DISCUSSION 
The results  reported in this paper have extended our concept of the C3  ac- 
tivator system (Fig. 5). Conversion of C3PA to C3 activator, an enzyme which 1006  C3  PROACTIVATOR CONVERTASE 
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FIG. 2.  Sedimentation behavior of C3PAse in a-globulin fraction (top), C3PAse in whole 
human  serum  (middle),  and isolated HSFa (bottom). Ultracentrifugation was performed in a 
linear 7-31%  sucrose density gradient at 45,000  rpm  in a  SW50 rotor  (Spinco  Div., Beck- 
man Instruments, Inc., Palo Alto, Calif.) for 16 hr at 4°C. 
F[o.  3.  The mode of action of C3PAse explored by immunoelectrophoresis.  (A)  Treat- 
ment of serum with HSFa led to conversion of C3PA;  (B)  C3PA in serum incubated with 
buffer was unconverted;  (C)  partially purified C3PAse and  Me  ++ failed to convert isolated 
C3PA;  (D)  isolated C3PA was converted, however, by C3PAse, Me  ++, and HSFa;  (E)  this 
reaction was  totally inhibited by 0.01  M EDTA;  (F)  HSFa and Me  ++ were without  effect 
on isolated C3PA; (G) native C3 was unaffected when treated with C3PA, HSFa, and Me++; 
(H) but totally converted by C3PA, C3PAse, HSFa, and Me  ++. Before application all sam- 
ples received EDTA (up to 0.02 •)  and the agar gel contained 0.01 ~t EDTA. Patterns A-F 
were developed with anti-C3PA, G and H with anti-C3. Anode was at the right. 
cleaves  C3  into  C3a  and  C3b,  is  accompanied  by fragmentation  of the  C3PA 
molecule.  This reaction  is  catalyzed  by  the  enzyme  C3PAse,  a  3S  a-globulin, 
which for its action on C3PA requires metal ions and a fragment of C3  (HSFa) 
which  might  be identical  with  C3b.  The  fragment  appears  to  fulfill the  func- 
tion  of  an  enzyme  effector  or  modifier;  its  precursor,  native  C3,  representing HANS J.M~'LLER-EBERHARD AND  OTTO GOTZE  1007 
the previously recognized N2H4-sensitive factor (1). C3b, or a fragment closely 
resembling it, is thus envisioned to play a key role in the C3 activator system; 
as  one  of the final  products  of the  reaction  it  can  "switch  on"  C3PAse  and 
thereby  initiate  a  positive  feedback  mechanism. 
An effector function of a protein fragment in the complement system is not 
without  precedent.  Thus,  C4i  has  been  shown  to  uncover  the  specificity  of 
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FIG. 5.  Hypothetical  concept of a portion of the C3 activator mechanism proposing that 
a C3 fragment (here designated C3b) has an effector function for C3PAse. The possible control 
of this fragment by a serum factor is indicated  (C3b inactivator?).  The initiation of the reac- 
tion by inulin, etc., requires additional  serum factor(s)  (enzyme?). 
CI for C2 (5),  and a peptide related to kallikrein was found to  enhance C4,2- 
forming  activity of C1  (6).  Most pertinent  to the present  study is  the  effect 
of C3b on C4,2; in modifying this  enzyme C3b enables it to  act  on  C5  (4). 
How  substances  like  inulin  set  in  motion  the  proposed  mechanism  when 
added to serum is still unknown. A direct action of inulin on C3PAse was ruled 
out by the reported  experiments.  Perhaps  inulin  acts together with  an as yet 
unidentified  serum  factor  (enzyme?)  and  C3  on  C3PAse.  That  the  missing 
factor might be properdin has been considered (1), especially since the activity 
of our isolated C3PA could be equated with Factor B  activity of the properdin 
system  (7).  More  work is  needed  to fit  the  reaction  described  in this  paper 
FIG. 4.  Detection  of C3PAse in electrophoreticaUy separated  human serum. Conditions 
of electrophoresis: l~evikon block in barbital  buffer, pH 8.6, ionic strength  0.05, containing 
0.002 ~ EDTA, 3.5 v/cm/or 23 hr at 4°C. 
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into  the  entire  C3-activator  mechanism.  The  possibility exists  that  it  con- 
stitutes  an  analogue  to  the fluid-phase reactions  of the  classical complement 
activation system (4). In this case, the three recognized factors of the bypass 
mechanism  might  enter into  a  multimolecular arrangement  on  the  surface  of 
the activating substance added to whole serum. 
In view of the proposed effector function  of HSFa, it seems probable that 
its activity is controlled by a  regulatory principle in serum. A  possible candi- 
date is the C3b inactivator, which is known to degrade C3b enzymatically (8). 
Our  results may aid clarification of the mechanism underlying congenital  C3 
hypercatabolism (9). 
SUMMARY 
The  activity  in  human  serum  which  is  responsible  for  conversion  of  C3 
proactivator (C3PA)  to  C3  activator was shown  to reside in a  3S a-globulin. 
The factor, called C3PA convertase (C3PAse), was obtained in partially puri- 
fied form.  For conversion  of  C3PA,  C3PAse  required  participation of metal 
ions and of a  C3 fragment, which in physicochemical and antigenic properties 
resembled C3b.  Isolated, native C3 failed to substitute for the fragment,  but 
did  restore  the  impaired  C3  activator  system  in  hydrazine-treated  serum. 
Unlike  native  C3,  the  C3  fragment  initiated conversion  of  C3PA  in  whole 
serum.  A  hypothetical concept which envisions the C3  fragment  as effector of 
C3PAse has been proposed. 
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